Similarly, TIDE simplifies immune evasion into a few gene markers (e.g., PD–1, CTLA–4), and its model is mainly trained on melanoma and non-small-cell lung cancer (NSCLC) data, potentially limiting its applicability to CRC due to distinct tumor biology and immune contexts. This evidence concerns the gene CTLA4 and melanoma.